BHVN

Rating neutralAI MemoPost-earnings T+3

Biohaven

As of 2026-08-06/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Opakalim pivotal epilepsy data • 2026-11-04

Base target: $15 / p=50% prob

Biggest risk

The thesis remains exposed to binary clinical outcomes, execution delays, leadership-transition uncertainty [#8-K-2026-07-09], and potential funding or dilution sensitivity. No verified Q2 earnings surprise or guidance signal reduces near-term visibility.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Positive H2 2026 opakalim and obesity data, plus continued degrader-trial execution, could materially increase pipeline value. The packet median analyst target is $22.9333, but the analyst count is unavailable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-06

Base target

$15

p=50%

Bull target

$24

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 2026 earnings confirmation remains an evidence gap
Degrader-platform pivotal execution
Positive H2 2026 opakalim and obesity data, plus continued degrader-trial execution, could materially increase pipeline value.

BearKey bullets

Leadership transition announced in July adds execution uncertainty [#8-K-2026-07-09].
No verified Q2 2026 earnings release, guidance update, analyst revision, or post-print price-reaction decomposition was available.
Opakalim and taldefgrobep readouts are binary clinical events with meaningful efficacy, safety, timing, and regulatory risk.

WatchKey bullets

Opakalim pivotal epilepsy data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $15 (p=50%)

Target spread vs base: +66% / -38%

Scenario probabilities

Bull Target: $24 (p=25%)Base Target: $15 (p=50%)Bear Target: $9 (p=25%)

Commentary

News tone is mixed: clinical milestones support optionality, while leadership changes and the absence of verified Q2 earnings follow-up limit confidence. The stock anchor is $13.63 as of 2026-08-05. Social coverage, options data, short interest, employee sentiment, analyst revisions, and a clean post-earnings reaction attribution are unavailable; this remains a cautious monitoring setup.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 2026 earnings confirmation remains an evidence gap
Degrader-platform pivotal execution

Scenarios

Bull Target (Scenario probability)

$24 / p=25% prob

Base Target (Scenario probability)

$15 / p=50% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.50

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-04
Opakalim pivotal epilepsy data
Biohaven expects topline results from its pivotal opakalim epilepsy program in the second half of 2026, creating a binary validation point for a late-stage asset [#SEC-8K-2026-05-04].
Prob 65.00% • Move 20.00% • Priced-in 45.00%
EVENT2026-11-04
Taldefgrobep obesity topline data
The Phase 2 taldefgrobep alfa obesity study completed enrollment, with topline data expected in the second half of 2026 [#SEC-SEC-8K-2026-05-04].
Prob 55.00% • Move 18.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Q2 2026 earnings confirmation remains an evidence gap
2026-08-06
No verified Q2 2026 EPS, revenue, guidance change, transcript, or company earnings release was available in the packet or checked sources as of 2026-08-06. The latest usable earnings source is the Q1 SEC 8-K, which highlighted upcoming clinical milestones [#SEC-8K-2026-05-04].
Prob 70% • Move -2% • Priced-in 0%

Long-term Catalysts

Months to a year

Degrader-platform pivotal execution
2027-08-06
BHV-1300 and BHV-1400 are advancing toward pivotal development in Graves’ disease and IgA nephropathy, with trial initiation and execution remaining key portfolio milestones [#SEC-8K-2026-05-04].
Prob 70% • Move 12% • Priced-in 50%

Risks

Leadership transition announced in July adds execution uncertainty [#8-K-2026-07-09].
No verified Q2 2026 earnings release, guidance update, analyst revision, or post-print price-reaction decomposition was available.
Opakalim and taldefgrobep readouts are binary clinical events with meaningful efficacy, safety, timing, and regulatory risk.
Peer coverage is loose, while analyst-count, options, short-interest, and social data are unavailable.
The packet’s 10-Q excerpt references equity-distribution activity but lacks enough fresh cash-runway detail to quantify financing or dilution risk [#SEC-10Q-2026-05-04].

Peers

Symbol	Summary
HCM	Same-sector, similar-size biotech comparator; useful mainly for binary clinical-readout and financing-risk framing, not direct operating valuation.
RAPP	Same-sector, similar-size clinical-biotech comparator; the peer relationship is loose and offers limited direct read-through to Biohaven’s diversified pipeline.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

Loading AI feed…

Symbol

Summary

HCM

Same-sector, similar-size biotech comparator; useful mainly for binary clinical-readout and financing-risk framing, not direct operating valuation.

RAPP

Same-sector, similar-size clinical-biotech comparator; the peer relationship is loose and offers limited direct read-through to Biohaven’s diversified pipeline.